Intellia Therapeutics
Andrew Cho, Ph.D., is a Senior Scientist specializing in Analytical Science and RNA Chemistry at Intellia Therapeutics, Inc. since March 2023, where significant contributions include the acquisition and setup of advanced mass spectrometry equipment for RNA characterization. Previously, Andrew held roles at Magenta Therapeutics from July 2021 to February 2023, including Senior Scientist in Mass Spectrometry and Scientist II in DMPK, focusing on the implementation of software tools for analytical processes. Andrew's earlier experience includes work as an Analytical Chemistry Scientist at Sonic Reference Laboratory and a technician trainee at Trinity Pharmacy. Andrew holds a Bachelor of Science in Chemistry from The University of Texas at Austin and a Ph.D. in Analytical Chemistry from Texas Tech University.
Intellia Therapeutics
9 followers
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.